Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2012 Nov 1.

Published in final edited form as: Gene Ther. 2011 Oct 20;19(5):576–581. doi: 10.1038/gt.2011.138

FIG. 4 — Biodistribution of i.n. administered BAAV–Luc. Four mice per group were injected with 200ul of PBS containing none or 3mg of TA prior to i.n. delivery of 5^.10⁹ DRP of BAAV-Luc. 24 hrs or 8 weeks post treatment respectively mice received luciferin substrate then were sacrificed and expression quantified. (A) Luciferase activity of representative mice receiving BAAV alone or BAAV+TA 24 hrs post transduction. (B and C) Average luciferase activity of whole lung or stomach respectively of mice receiving BAAV alone (control) or BAAV+TA (TA), 24 hrs or 8 weeks post treatment respectively. Medians represented by horizontal lines. Student’s t-test * P value <0.05.

FIG. 4 — Biodistribution of i.n. administered BAAV–Luc. Four mice per group were injected with 200ul of PBS containing none or 3mg of TA prior to i.n. delivery of 5^.10⁹ DRP of BAAV-Luc. 24 hrs or 8 weeks post treatment respectively mice received luciferin substrate then were sacrificed and expression quantified. (A) Luciferase activity of representative mice receiving BAAV alone or BAAV+TA 24 hrs post transduction. (B and C) Average luciferase activity of whole lung or stomach respectively of mice receiving BAAV alone (control) or BAAV+TA (TA), 24 hrs or 8 weeks post treatment respectively. Medians represented by horizontal lines. Student’s t-test * P value <0.05.